Skip to main content

Table 1 AML patient characteristics

From: Early changes in gene expression profiles in AML patients during induction chemotherapy

Patient ID

Year of diagnosis

Age

Induction treatment regime

Blast count at baseline

Leukocyte paticle count at baseline (× 109/L)

Leukocyte particle count Day 2 (48 h)

(× 109/L)

Cytogenetics

FLT3- ITD

NPM1 mutation

CEBPA mutation

Morphological complete remission after inductionc

1

2001

67

Idarubicin and cytarabine

80% (BM), 60% (PB)

60,8

58

Aberrant expression of T-cell markers

NA

NA

NA

No

2

2001

81

Daunorubicin and cytarabinea

NA

93

75,9

NA

NA

NA

NA

Yes

3

2003

39

Daunorubicin and cytarabinea

20% (PB)

51,7

31,6

Normal karyotype

No

No

NA

Yes

4

2001

67

Cladribine, cytarabine and idarubicin

90% (BM)

72

1,9*

Trisomy 8

NA

NA

NA

Yes

5

2003

66

Daunorubicin and low-dose cytarabineb

40% (BM)

35,8

11,2

1-40dmin [22] /46XY [3]

Yes

No

NA

No

6

2015

64

Daunorubicin and cytarabine

78% (BM), 57% (PB)

1,6

0,7

Normal karyotype

No

Yes

Heterozygous

Yes

7

2015

74

Daunorubicin and cytarabine

88% (BM)

164

2,6

Not possible due to no mitoses after culturing

NA

NA

NA

No

8

2015

73

Daunorubicin and cytarabine

60% (BM), 77% (PB)

135

37

Normal karyotype

Yes

No

No

No

9

2016

21

Daunorubicin and cytarabine

75% (BM), 44% (PB)

68

5,2

47XY, inv.(16)(p13;q22), +mar [23]

No

No

NA

Yes

10

2016

46

Daunorubicin and cytarabine

32% (BM), 2% (PB)

7,4

3,4

Complex karyotype

No

No

No

No

  1. aInitially only cytarabine; no daunorubicin during study sample collection
  2. bAfter one previous day of all-trans-retinoic acid (ATRA) treatment
  3. cBone marrow evaluated at day 15–28 after the start of induction chemotherapy
  4. *Leukocyte particle count available also from Day 1 (24 h); 32*109/L